Stimulates sustained, dose-dependent GH and IGF-1 secretion while preserving natural pulsatile GH pattern. Covalent albumin binding (DAC) extends half-life to 6-8 days. Resistant to DPP-4 degradation.
GH optimization, body composition, anti-aging (compounding, off-label). Often combined with Ipamorelin despite zero published combination RCT evidence.
Active malignancy. Diabetes/insulin resistance. History of pituitary disorders.
Phase I/II human data confirmed GH/IGF-1 elevation. Phase II discontinued after participant death.
- 1.Ionescu et al., JCEM 2006 — sustained GH secretion and dose-response characterization
- 2.Teichman et al., JCEM 2006 — pharmacokinetics and GH response profile. Phase II subsequently discontinued after participant death
Phase II discontinued after participant death. NO body composition or performance outcomes from any completed RCT. Often conflated with CJC-1295 without DAC (mod GRF 1-29) — different compounds.
Commonly combined with Ipamorelin in clinical practice despite zero published combination RCT data.